Hodgkin Lymphoma 
Welcome,         Profile    Billing    Logout  

547 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hodgkin Lymphoma
ChiCTR-TRC-09000400: Gemcitabine for Classical Hodgkin's Lymphoma

Completed
4
60
 
The chemotherapy plan is the same with the control group.In addition to ABVD therapy, Gemcitabine 900mg/m2 will be added on Day 1 and 15 for each coursed. ;ABVD chemotherapy. For stage II patients, 6 courses of ABVD chemotherapy are planned. For Stage III and IV patients. 8 coursed of ABVD chemotherapy are planned.
West China Hospital, Sichuan University; Level of the institution：, Department of Hematology West China Hospital
Hodgkin's Lymphoma
 
 
2014-001561-27: Neuropathy caused by vincristine in children with leukemia: comparing one-hour infusions with short-term infusions Neuropathie door vincristine bij kinderen met leukemie: één-uurs infusen vergeleken met kortdurende infusies

Ongoing
4
88
Europe
Vincristine sulfate, Vincristine Sulphate, VCR, Solution for infusion, Solution for injection
VU university medical center, The Netherlands Organisation for Health Research and Development (in Dutch: ZonMw)
Pediatric oncology, acute lymphoblastic leukemia, nephroblastoma, medulloblastoma, low-grade glioma, Hodgkin lymphoma, rhabdomyosarcoma Kinderoncologie, acute lymfatische leukemie, nefroblastoom, medulloblastoom, laaggradig glioom, Hodgkin lymfoom en rhabdomyosarcoom, Childhood cancer Kinderkanker, Diseases [C] - Cancer [C04]
 
 
2014-002226-13: Advanced imaging for identifying chemotherapy-induced cardiac damage in lymphoma patients

Ongoing
4
100
Europe
Concentrate and solvent for solution for infusion, Adriamycin/Doxorubicin
Rigshospitalet, Danish Cancer Association
Hodgkin and non-Hodgkin lymphoma, Malignant lymphoma, a cancer of a subgroup of the white blood cells called lymphocytes., Diseases [C] - Immune System Diseases [C20]
 
 
2011-005554-62: A study investigating the pharmcokintetics (how the body processes with a drug) and pharmcodynamics (what effect the drug has on the body) of the chemotherapy drug doxorubicin, when used to treat children, adolescents and young adults with newly diagnosed cancers: osteosarcoma, Ewing\'s family of tumours, and Hodgkin lymphoma.

Ongoing
4
30
Europe
doxorubicin, Doxorubicin, Doxorubicin, Doxorubicin
Australian Sarcoma Group (ASSG), ASSG (Australian Sarcoma Study Group)
Ewing family of tumoursOsteosarcomaHodgkin lymphoma
 
 
2020-001856-16: Evaluation of the Relationship Between Therapeutical Antibody Exposure and Tumor VOLUME in Patients Treated for Conventional HODgkin's Lymphoma Evaluation de la RElation entre exposition à un anticorps thérapeutique et VOLUme tumoral chez le patient traité pour un lyMphome de HODgkin classique

Not yet recruiting
4
50
Europe
OPDIVO, KEYTRUDA, BMS-936558, Concentrate for solution for infusion, OPDIVO, KEYTRUDA
Rennes University Hospital, Cancer Translational Research Program
Refractory Hodgkin Lymphoma Lymphome de Hodgkin réfractaire, Hodgkin Lymphoma Lymphome de Hodgkin, Diseases [C] - Cancer [C04]
 
 
2021-001107-33: SARS-CoV-2 vaccination response in patients with haematologicaldisease Respons op SARS-Cov-2 vaccinatie in patiënten met een hematologischeziekte

Ongoing
4
743
Europe
Comirnaty, Suspension for injection in pre-filled injector, Comirnaty
MUMC, MUMC
multiple myeloma (including MGUS)chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloidleukemia, acute lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkinlymphoma, myelodysplastic syndrome, myeloproliferative disease), haematological disease defined as:MM, MGUS, CLL, CML, AML, ALL, NHL, HL, MDS, MPN, Body processes [G] - Immune system processes [G12]
 
 
ChiCTR2000033441: Tislelizumab plus Gemox in relapsed or refractory patients with cHL

Not yet recruiting
4
30
China
Tislelizumab plus Gemox
Anhui Provincial Cancer Hospital ; Anhui Provincial Cance Hospital, Self-collected
cHL
 
 
ChiCTR2100048232: Clinical study of BeEAM (bendamustine, etoposide, cytarabine, melphalan) regimen for preconditioning before lymphoma autotransplantation

Not yet recruiting
4
50
 
Bendamustine + cytarabine + etoposide + macfaran
He'nan Provincial People's Hospital; He'nan Provincial People's Hospital, self-funded
lymphoma
 
 
ChiCTR2000033599: PD-1 monoclonal antibody (tirelizumab) alternative radiotherapy for children with classic Hodgkin's lymphoma: a prospective, one-arm, open-label real-world study

Recruiting
4
40
China
Intravenous Tislelizumab
Beijing Boren Hospital ; Beijing Boren Hospital, Self-raised
Children's classic Hodgkin's lymphoma
 
 
EuroNetLP1, NCT01088750 / 2007-004092-19: Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Completed
4
225
Europe
cyclophosphamide, CYC, prednisolone, PRED, vinblastine sulfate, VBL, watchful waiting, therapeutic conventional surgery
Christine Mauz-Körholz, Deutsche Krebshilfe e.V., Bonn (Germany), Euronet Worldwide
Lymphoma
10/23
10/23
ChiCTR2000035463: A real-world prospective clinical study of carilizumab in the treatment of immune related endocrine diseases in patients with advanced malignant tumors

Not yet recruiting
4
198
 
none
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiansu Hengrui Pharmaceuticals Co. Ltd.
Advanced malignant tumors
 
 
NCT05490953: Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma

Recruiting
4
30
RoW
Pentoxifylline, Experimental Group, Placebo, Placebo Group
University of Guadalajara, Hospital Civil de Guadalajara
Hodgkin Lymphoma
12/23
07/24
ChiCTR2100048295: Clinical study of BeEAM (bendamustine, etoposide, cytarabine, melphalan) regimen for preconditioning before lymphoma autotransplantation

Recruiting
4
50
 
Bendamustine + cytarabine + etoposide + macfaran
He'nan Provincial People's Hospital; He'nan Provincial People's Hospital, self-funded
lymphoma
 
 
NCT04726501: CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma

Recruiting
4
200
RoW
Combined chemotherapy with or without involved-field radiotherapy
Children's Cancer Group, China, Shanghai Children's Medical Center
Hodgkin Lymphoma
12/25
12/27
LHGALOP2017, NCT03500133: Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

Recruiting
4
500
RoW
No radiotherapy if CR at the end of chemotherapy., Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered., Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered., IN 30Gy RT in case of PR at the end of chemotherapy, Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered., Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD., High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD., High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD., Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Hospital JP Garrahan, Hospital Pereyra Rosell, Montevideo, Uruguay
Pediatric Hodgkin's Disease
10/27
10/32
2020-004780-71: A study using a hormone drug during chemotherapy for fertility protection of young women and teenagers with cancer - ProFertil En studie med ett hormonpreparat som utvärderar effekten av fertilitet hos unga kvinnor och tonåringar med cancer - ProFertil

Not yet recruiting
3
500
Europe
Pamorelin, Powder and solvent for prolonged-release suspension for injection, Pamorelin
Karolinska University Hospital, Karolinska University Hospital
Breast CancerAcute LeukemiaLymphomas (Hodgkin and non-Hodgkin)Sarcomas (Osteo, Soft tissue and Ewing) Bröstcancer, Akut Leukemi, Lymfom (Hodgkin och non-Hodgkin), Sarkom (Ben, Mjukvävnad och Ewing), Breast CancerBlood CancerCancer in lymphnodesCancer in bones Bröstcancer, Blodcancer, Cancer i lymfkörtlar, Cancer i skelett, Diseases [C] - Cancer [C04]
 
 
2010-022844-19: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma

Ongoing
3
810
Europe
Bleomycin, Prednisone, Vincristine, Doxorubicin, Cyclophosphamide, Dacarbazine, Etoposide, Procarbazine, Vinblastine, Powder for solution for injection, Tablet, Solution for injection, Powder for solution for infusion, Solution for infusion, Capsule*
CHU de Dijon
Hodgkin Lymphoma not previously treated
 
 
NCT00379041: Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Active, not recruiting
3
1158
NA
bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
10/98
 
NCT00002462: RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

Active, not recruiting
3
615
Europe, RoW
bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
05/00
 
NCT00005584: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Active, not recruiting
3
1649
Europe
bleomycin sulfate, ABVD regimen, BEACOPP regimen, epirubicin hydrochloride, prednisone, vinblastine sulfate, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, UNICANCER
Lymphoma
05/04
 
2009-017279-77: Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non hodgkin's lymphoma CD 20+ Phase III randomisée multicentrique évaluant la non infériorité d’un traitement adapté à la réponse précoce au morphoTEP par rapport à un traitement standard pour les patients de 18 à 80 ans atteints d’un lymphome malin non hodgkinien B diffus à grandes cellules CD 20 + de faible risque (IPI aa=0)

Ongoing
3
650
Europe
rituximab, Prednisone, Doxorubicine, Cyclophosphamide, Vincristine, G-CSF, Concentrate for solution for infusion, Tablet, Solution for injection, Powder for injection, Unknown (not supplied)
LYSARC, INCa
Patient with Diffuse Large B cells with IPI=0 not previously treated, Patient with Diffuse Large B cells with IPI=0 not previously treated, Diseases [C] - Cancer [C04]
 
 
NCT00433433 / 2005-002765-37: Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Active, not recruiting
3
1952
Europe
ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual), Involved-Note Radiation Therapy, FDG-PET scan, F-18 fluorodeoxyglucose positron emission tomography scan
European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, Fondazione Italiana Linfomi ONLUS
Lymphoma
12/11
 
2009-010700-28: GRANITE-1 - Transmission of specific immune cells from healthy donors for cancer patients with fever, who lack these cells

Ongoing
3
200
Europe
Granulocyte-Transfusion, Granocyte-13, Neupogen 30, Neupogen 48, Granocyte 34, no product code available, Infusion, Powder and solvent for solution for injection, Solution for injection, GRANOCYTE 13, NEUPOGEN 30, NEUPOGEN 48, GRANOCYTE 34
University of Cologne, Deutsche Forschungsgesellschaft (DFG)
Febrile neutropenia due to chemotherapy for the following diseases:C92.0- - Acute myeloid leukemiaC91.0- - Acute lymphoblastic leukemiaC92.1- - Chronic myeloid leukemiaC91.1- - Chronic lymphoblastical leukemiaD46.9 - Myelodysplastic syndromeD47.1 - Chronic myeloproliferative diseaseC82.- - Follicular/nodular NHLD83.- - Diffuse Non-Hodgkin's Lymphoma (NHL)C84.4 - Peripheral T-Cell NHLC90.0- - Multiple myelomaC81.9 - Hodgkin's lymphoma (HL), Patients with cancer of the blood or the immunesystem who have a weak immunesystem due to chemotherapy,who develope fever during the time of a weak immunesystem can take part in this study., Diseases [C] - Cancer [C04]
 
 
ACTRN12610000927022: A randomised Phase III Trial to assess response adapted therapy using 2-[F-18]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma

Completed
3
1200
 
University College, National Health and Medical Research Council
Hodgkin Lymphoma
 
 
RAPID, NCT00943423: PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

Active, not recruiting
3
602
Europe
Involved Field Radiotherapy, No further treatment
University College, London, The Christie NHS Foundation Trust
Lymphoma
07/14
12/28
2007-005831-27: Use of rHuEpo before autologous hematopoietic stem cell transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer to reduce transfusional requirement after myeloablative conditioning. A monocentric, phase III, open study.

Ongoing
3
90
Europe
EPREX, EPREX
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA\' GRANDA (A.O. DI RILIEVO NAZIONALE)
autologous hematopoietic stem cells transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer
 
 
2007-000230-39: Protective effect of gonadoliberin analogues on endocrine and reproduction ovarian function during antitumour treatment in young girls and women in fertile period: Project of pharmacological gonadal protection and protection of reproduction functions.

Ongoing
3
40
Europe
Diphereline S.R. 3 MG INJ, DIPHERELINE S.R. 3mg, DIPHERELINE S.R. 3mg
Endocrine Society of Czech Republic
The patient with diagnosis: Hodgkin disease and leukaemia. Patients starting at adolescence (B3 - B4 for breast development accordig Tanner criteria) till 34 years be included.
 
 
2007-003187-22: HD18 for advanced stages HD18 für fortgeschrittene Stadien

 
3
1600
Europe
Bleomycin, Etoposide, Doxorubicine, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Bleomycin, Etoposid, Doxorubicin, Endoxan, Oncovin, Procarbazine, Prednisone, Bleomycin, Etoposid, Doxorubicin, Endoxan, Oncovin, Procarbazine, Prednisone
University of Cologne, VU University Medical Center, , Deutsche Krebshilfe
Hodgkin´s lymphomaadvanced stage
 
 
2008-002684-14: Early salvage with high dose chemotherapy and stem cell transplantation in advanced stage Hodgkin’s lymphoma patients with positive positron emission tomography after two courses of ABVD (PET-2 positive) and comparison of radiotherapy versus no radiotherapy in PET-2 negative patients.

Ongoing
3
300
Europe
DOXORUBICINA BAXTER*EV 20FL50M, BLEOMICINA NIPPON K.*1F 15MG, VINBLASTINA BAX*INFUS 1FL 10MG, DETICENE*INFUS 100MG/10ML FL+F, DOXORUBICINA BAXTER*EV 20FL50M, BLEOMICINA NIPPON K.*1F 15MG, VINBLASTINA BAX*INFUS 1FL 10MG, DETICENE*INFUS 100MG/10ML FL+F
IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
HODGKIN LYMPHOMA
 
 
2007-004474-24: HD16 für frühe StadienTherapieoptimierungsstudie in der Primärtherapie des frühen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET

Ongoing
3
1150
Europe
Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, L01DB01, L01DC01, L01CA01, L01AX04, Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
University of Cologne, VU University Medical Center, , Deutsche Krebshilfe
Hodgkin´s Lymphoma early stage
 
 
RATHL, NCT00678327 / 2007-006064-30: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Completed
3
1202
Europe
bleomycin sulfate, filgrastim, pegfilgrastim, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisolone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate
University College, London, Cancer Research UK, Cancer Research UK & UCL Cancer Trials Centre
Lymphoma
01/16
05/24
2011-000088-28: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial

Ongoing
3
300
Europe
Sirolimus, Mycophenolatmofetil, Cyclosporine, EU/1/01/171/007, EU/1/01/171/001, EU/1/96/005/001, EU/1/96/005/004, EU/1/96/005/005, Coated tablet, Oral liquid, Capsule, Tablet, Powder for concentrate for solution for infusion, Capsule, soft, Oral suspension, Concentrate and solvent for concentrate for solution for infusion, Rapamune, CellCept, Sandimmun
Fred Hutchinson Cancer Research Center
Graft versus host disease, Graft versus host disease is a process where donor cells may react against cells of your body causing inflammation that can involve the skin, liver and gastrointestinal system., Not possible to specify
 
 
ECHELON-1 , NCT01712490 / 2011-005450-60: A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Checkmark Six year data from ECHELON-1 study for advanced classical Hodgkin lymphoma
Jul 2022 - Jul 2022: Six year data from ECHELON-1 study for advanced classical Hodgkin lymphoma
Checkmark Full data from ECHELON-1 trial in Hodgkin lymphoma at ASCO 2022
May 2022 - May 2022: Full data from ECHELON-1 trial in Hodgkin lymphoma at ASCO 2022
Checkmark Five year data from ECHELON-1 study for advanced classical Hodgkin lymphoma at ASH 2020
More
Active, not recruiting
3
1334
Europe, Canada, Japan, US, RoW
brentuximab vedotin, ADCETRIS®, SGN-35, doxorubicin, Adriamycin, bleomycin, vinblastine, dacarbazine, DTIC
Takeda, Seagen Inc.
Hodgkin Lymphoma
04/17
01/26
HD16, NCT00736320: for Early Stage Hodgkin Lymphoma

Active, not recruiting
3
1150
Europe
ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine), 20 Gy IFRT (Involved Field Radiotherapy)
University of Cologne
Hodgkin Lymphoma
09/18
12/21
ACTRN12618000069257: European Network-Paediatric Hodgkin Lymphoma Study Group: Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Active, not recruiting
3
160
 
Justus Liebig University of Giessen, My Room - Children's Cancer Charity
Classical Hodgkin Lymphoma
 
 
2021-001385-38: RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA NEEDING RADIATION THERAPY ON THYROID SITE Studio randomizzato per proteggere da ipotiroidismo iatrogeno dovuto ad irradiazione pazienti con medulloblastoma (qualsiasi età, stadio e qualsiasi rischio biologico) e pazienti pediatrici con linfoma di Hodgkin e linfoma non-Hodgkin che necessitano di radioterapia includente la sede tiroidea

Ongoing
3
51
Europe
Levotiroxina, [Levotiroxina], Tablet
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
medulloblastoma, Hodgkin and non-Hodgkin lymphomas medulloblastoma, linfomi di Hodgkin e linfomi non-Hodgkin, medulloblastoma, Hodgkin and non-Hodgkin lymphomas medulloblastoma, linfomi di Hodgkin e linfomi non-Hodgkin, Diseases [C] - Cancer [C04]
 
 
FIL-Rouge, NCT03159897 / 2016-002509-21: FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Active, not recruiting
3
500
Europe
Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/21
09/24
AHOD1331, NCT02166463: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Checkmark Data from the AHOD1331 trial in children with newly diagnosed high-risk Hodgkin lymphoma at ASCO 2022
Jun 2022 - Jun 2022: Data from the AHOD1331 trial in children with newly diagnosed high-risk Hodgkin lymphoma at ASCO 2022
Active, not recruiting
3
600
Canada, US
Bleomycin Sulfate, Blanoxan, BleMomycine, Blenoxane, Bleo-cell, Bleo-S, Bleocin, Bleolem, Bleomycin Sulfas, Bleomycin Sulphate, Bleomycini Sulfas, Blexane, Oil Bleo, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Laboratory Biomarker Analysis, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
12/21
09/24
ACTRN12617000087358: Treatment optimisation trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD.

Active, not recruiting
3
1585
 
University of Cologne, Millennium Pharmaceuticals
Advanced stage Hodgkin lymphoma
 
 
2022-000371-39: MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma

Ongoing
3
360
Europe
MK4280A (Favezelimab + Pembrolizumab), MK4280A, Solution for infusion, Bendamustine, Gemcitabine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma, Relapsed or Refractory Classical Hodgkin Lymphoma, Diseases [C] - Cancer [C04]
 
 
Uni-Koeln-1762, NCT02661503 / 2014-005130-55: HD21 for Advanced Stages

Active, not recruiting
3
1500
Europe
Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Brentuximab Vedotin, Dacarbazine, Dexamethasone
University of Cologne
Classical Hodgkin Lymphoma
12/22
09/25
NCT03480360: Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Active, not recruiting
3
20
US
Cyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept, g-csf, Peripheral Blood Transplant
Dartmouth-Hitchcock Medical Center
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
03/23
09/25
MI-Immune, NCT03959241: TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Completed
3
431
US
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, HSCT, Tacrolimus, Prograf®, FK506, Methotrexate, MTX, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, CellCept®, MMF, Cyclophosphamide, Cytoxan®
Medical College of Wisconsin, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
09/22
09/22
NCT04044222: A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Recruiting
3
240
RoW
Sintilimab, Carboplatin, Etoposide, Ifosfamide, Placebo
Innovent Biologics (Suzhou) Co. Ltd.
Classic Hodgkin's Lymphoma
07/23
12/24
NCT04342936: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
3
56
RoW
Camrelizumab, SHR-1210, Investigator's choice of Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Classical Hodgkin Lymphoma
08/23
12/23
NCT06170489: A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Recruiting
3
185
RoW
JS004 in combination with Toripalimab, Bendamustine or gemcitabine
Shanghai Junshi Bioscience Co., Ltd.
Hodgkin Lymphoma
05/25
09/27
HL-Russia-1, NCT04638790: First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia

Recruiting
3
300
RoW
Doxorubicin, ABVD, Bleomycin, Vinblastine, Dacarbazine, Etoposide, EACODD-14, Cyclophosphamide, Vincristine, Dexamethasone
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Hodgkin Lymphoma, Adult
12/23
12/26
SWOG S1826, NCT03907488: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Active, not recruiting
3
995
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-jmdb, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
03/24
04/25
NCT06465446: A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting
3
202
NA
Tislelizumab, IMM01, Timdarpacept, Bendamustine, Gemcitabine
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Classic Hodgkin Lymphoma
06/26
07/29
ReSPECT, NCT04368559 / 2017-004981-85: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
3
600
Europe, Canada, US, RoW
Rezafungin for Injection, Intravenous antifungal therapy, Posaconazole, Noxafil, Fluconazole, Generic Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Bactrim, Septra, Intravenous Placebo, Placebo Infusion, Oral Placebo, encapsulated cellulose
Mundipharma Research Limited
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
12/25
12/25
RATIONALE-314, NCT04486391: Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting
3
123
RoW
Tislelizumab, BGB-A317, Salvage Chemotherapy
BeiGene
Classical Hodgkin Lymphoma
09/24
03/25
OPTIMAL>60, NCT01478542 / 2010-019587-36: / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Checkmark P3 enrollment initiation in 1st line, adult NHL pts
Nov 2011 - Nov 2011: P3 enrollment initiation in 1st line, adult NHL pts
Completed
3
1152
Europe
Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab, optimised rituximab-schedule
Universität des Saarlandes, German High-Grade Non-Hodgkin's Lymphoma Study Group, Spectrum Pharmaceuticals, Inc
CD20+ Aggressive B-Cell Lymphoma
01/24
01/24
NCT04459416: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

Active, not recruiting
3
300
US
Acupuncture, opioid, Assessments
Memorial Sloan Kettering Cancer Center, Patient-Centered Outcomes Research Institute, Hackensack Meridian Health
Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
06/25
06/25
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/24
NCT05518318: GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Not yet recruiting
3
60
NA
GLS-010, GLS-010 therapy, Chemotherapy of Investigator's choice
Guangzhou Gloria Biosciences Co., Ltd.
Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/25
06/25
KEYNOTE-204, NCT02684292 / 2015-005053-12: Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/)

Checkmark From KEYNOTE-204 trial in r/r classical Hodgkin’s lymphoma
Feb 2022 - Feb 2022: From KEYNOTE-204 trial in r/r classical Hodgkin’s lymphoma
Checkmark Expanded label in Keytruda for treatment of patients with classical Hodgkin lymphoma (cHL) after prior therapies
Mar 2021 - Mar 2021: Expanded label in Keytruda for treatment of patients with classical Hodgkin lymphoma (cHL) after prior therapies
Checkmark Efficiancy & safety data from KEYNOTE-204 study compared to Keytruda for r/r chronic Hodgkin's lymphoma
More
Active, not recruiting
3
304
NA
pembrolizumab, MK-3475, KEYTRUDA®, brentuximab vedotin, ADCETRIS®
Merck Sharp & Dohme LLC
Hodgkin Lymphoma
07/25
07/25
NCT05244642: A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Recruiting
3
60
RoW
Penpulimab, AK105, Investigator's choice of Chemotherapy
Akeso, Beijing Cancer Hospital
Hodgkin Disease Lymphoma
12/25
03/26
NCT05466318: ChiCGB vs BEAM in High-risk or R/R Lymphomas

Recruiting
3
306
RoW
Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant
Sichuan University
Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell
12/25
12/25
BELINDA, NCT03570892 / 2016-002966-29: Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Checkmark From BELINDA trial for 2L DLBCL [Did not met primary end point]
Aug 2021 - Aug 2021: From BELINDA trial for 2L DLBCL [Did not met primary end point]
Active, not recruiting
3
331
Europe, Japan, US, RoW
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
02/26
02/26
NCT02684708: Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Active, not recruiting
3
2200
Europe, RoW
cyclophosphamide, vincristine, prednisone, dacarbazine, CYC, VCR, PRED, DTIC, cyclo, vcr, pred, dacarb,etop and doxo, CYC, VCR, PRED, DTIC, ETO, DOXO
University of Giessen, Deutsche Krebshilfe e.V., Bonn (Germany), Euronet Worldwide
Classical Hodgkin Lymphoma
09/26
09/26
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/27
12/29
ARCHED, NCT05820841: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

Recruiting
3
330
Europe
R-miniCHOP + Acalabrutinib, R-miniCHOP
Universität des Saarlandes, University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital of Gießen and Marburg, Saarland University Medical Center, AstraZeneca
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
04/28
12/28
NCT05711628: A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Withdrawn
3
334
NA
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Bendamustine, SDX-105, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Transplant Conditioning, conditioning regimen, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine
National Cancer Institute (NCI)
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/28
06/28
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
AHOD2131, NCT05675410: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
3
1875
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bleomycin Sulfate, Blanoxan, BleMomycine, Blenoxane, Bleo-cell, Bleo-S, Bleocin, Bleolem, Bleomycin Sulfas, Bleomycin Sulphate, Bleomycini Sulfas, Blexane, Oil Bleo, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Etoposide Phosphate, Etopophos, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Involved-site Radiation Therapy, ISRT, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Dacortin H, Decaprednil, Decortin H, Delta(1)Hydrocortisone, Delta- Cortef, Delta-Cortef, Delta-Diona, Delta-F, Delta-Phoricol, Delta1-dehydro-hydrocortisone, Deltacortril, Deltahydrocortisone, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Metacortandralone, Meti Derm, Meticortelone, Opredsone, Panafcortelone, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Predni-Helvacort, Prednicortelone, Prednisolonum, Prelone, Prenilone, Sterane, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Procarbazine Hydrochloride, Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI), Ibenzmethyzine hydrochloride, Matulane, MIH hydrochloride, Natulan, Natulanar, Natunalar, NCI-C01810, p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochloride, p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-, monohydrochloride (8CI), PCB, PCB Hydrochloride, PCZ, Ro 4 6467/1, Ro 4-6467/1, Questionnaire Administration, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
04/31
04/31
KEYFORM-008, NCT05508867 / 2022-000371-39: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Recruiting
3
360
Europe, Canada, US, RoW
favezelimab/pembrolizumab, MK-4820A, bendamustine, BENDEKA®, gemcitabine, GEMZAR®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Hodgkin Lymphoma
05/27
06/31
NCT00981760: Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Recruiting
2/3
20
US
Total Body Irradiation, TBI, Fludarabine, Recipient Leukocyte Infusion, RLI
Massachusetts General Hospital
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma
06/10
06/10
NCT04510610: Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting
2/3
100
RoW
Camrelizumab and Decitabine
Chinese PLA General Hospital
Hodgkin Lymphoma
01/22
01/25
NCT05595447: Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2/3
20
RoW
Brentuximab Vedotin 50 MG [Adcetris], Nivolumab, Pembrolizumab
Hospital Regional de Alta Especialidad del Bajio, Universidad de Guanajuato
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
10/25
10/25
NCT04799275: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Recruiting
2/3
422
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Oral Azacitidine, Azacitidine Oral, CC-486, Onureg, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
03/26
03/26
ACTRN12613001154796: A phase 2 trial of a preventative treatment (cyclophosphamide) for graft-versus-host disease after matched (HLA-identical) allogeneic donor transplant using less intensive chemotherapy

Not yet recruiting
2
24
 
Westmead Hospital, Westmead Hospital
Graft versus Host Disease, Haematological malignancy
 
 
ACTRN12612000137897: Dose-Dense ABVD Study: An accelerated delivery of Adriamycin, Bleomycin, Vinblastin and Dacarbazine for patients with Hodgkin Lymphoma

Not yet recruiting
2
31
 
Queensland Health, Hospira
Early Stage Unfavourable Hodgkin Lymphoma, Advanced Stage Hodgkin Lymphoma
 
 
ACTRN12622000207718p: A study of a chemotherapy regime and tislelizumab in elderly patients with Hodgkin Lymphoma

Not yet recruiting
2
35
 
Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group (ALLG)
Hodgkin Lymphoma
 
 
ACTRN12606000350527: Outpatient-based fractionated Ifosfamide, Carboplatin, Etoposide (ICE) chemotherapy supported with pegfilgrastim for salvage and stem cell mobilisation in transplant eligible patients with relapsed or refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

Recruiting
2
40
 
Amgen, Amgen
Relapsed or refractory diffuse large B-cell lymphoma and Hodgkin lymphoma
 
 
ACTRN12608000639325: Multicentre clinical study with early treatment intensification in patients with high-risk Hodgkin Lymphoma, identified as 18-F Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) scan positive after two conventional Doxorubicin, Bleomycin, Vinblastine, Dacarbazine (ABVD) courses

Recruiting
2
450
 
Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Gruppo Italiano Terapia Innovativa nei Linfomi
Hodgkin Lymphoma
 
 
ACTRN12605000380695: Induction Of Mixed Haematopoietic Chimerism In Patients Using Fludarabine, Low Dose Total Body Irradiation, Peripheral Blood Stem Cell Infusion And Post-Transplant Immunosuppression With Cyclosporine And Mycophenolate Mofetil

Active, not recruiting
2
40
 
A/Prof Durrant
Myelodysplastic syndromes., Myeloproliferative syndromes., Acute Leukemia with < 10% blasts., Amyloidosis, Hodgkins disease., Multiple Myeloma, Non-Hodgkins lymphoma, Chronic myeloid leukaemia, Chronic lymphocytic leukaemia, Renal cell carcinoma
 
 
ACTRN12617000151336: A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis

Recruiting
2
70
 
St Vincent's Hospital Sydney, Arrow Bone Marrow Transplant Foundation
Acute Myeloid Leukaemia in first or second complete remission, Chronic Myeloid Leukaemia prior to acute or blast transformation, acute Lymphoblastic Leukaemia in first or second complete remission, Non Hodgkin's Disease in remission, for Hodgkins Disease in remission, Myeloproliferative disease , Patient requiring a haplo-identical stem cell tranplant for Myelodysplastic syndrome with less than or equal 2 CIBMTR risk factors , transformed Acute Myeloid Leukaemia with less than or equal 2 CIBMTR risk factors , MDSIPSS, Acute Myeloid Leukaemia refractory disease with less than or equal 2 CIBMTR
 
 
ACTRN12619000581167: Brentuximab Vedotin in combination with donor lymphocyte infusions for Hodgkin lymphoma relapsing or persisting after allogeneic stem cell transplantation

Recruiting
2
10
 
Melbourne Health, Millenium Pharmaceuticals
Hodgkin lymphoma
 
 
ACTRN12622000207718: A study of a chemotherapy regime and tislelizumab in elderly patients with Hodgkin Lymphoma

Recruiting
2
35
 
Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group (ALLG)
Hodgkin Lymphoma
 
 
ACTRN12622001232729: A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation

Recruiting
2
127
 
St Vincent's Hospital, Sydney , St Vincent's Hospital, Sydney , Arrow Bone Marrow Transplant Foundation , Link (A Clinigen Company)
Acute Myeloid Leukaemia , Chronic Myeloid Leukaemia , Acute Lymphoblastic Leukaemia , Non Hodgkin's Disease , Hodgkin's Disease , transformed AML/ MDS , Myeloproliferative Disorders
 
 
2005-003369-17: A phase II Multi-Dose Study of SGN-30 anti-CD30 mAb in Patients with Refractory or Recurrent Hodgkin s Disease or Anaplstic Large Cell Lymphoma

Ongoing
2
80
Europe
Concentrate for solution for infusion
ISTITUTO NAZIONALE PER LA CURA TUMORI
Patients with Refractory or Recurrent Hodgkin s Disease or Anaplastic Large Cell Lymphoma
 
 
NCT00544115: Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting
2
260
NA
busulfan, cyclophosphamide, cyclosporine, etoposide, fludarabine phosphate, melphalan, methotrexate, mycophenolate mofetil, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
City of Hope Medical Center, National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition
03/07
12/24
NCT00060229: Pegfilgrastim Compared With Filgrastim To Increase Peripheral Stem Cells Before Autologous Stem Cell Transplantation in Treating Patients With Lymphoma

Active, not recruiting
2
US
filgrastim, pegfilgrastim, peripheral blood stem cell transplantation
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Lymphoma
 
 
2009-017587-16: Treatment monitoring using FDG-PET/CT and FLT-PET/CT in patients with Hodgkin Lymphoma.

Ongoing
2
20
Europe
Fluorodeoxyglucose (18F), Fluorothymidine, Solution for injection,
Barts Health NHS Trust
Hodgkin Lymphoma
 
 
2012-002418-38: Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted stem cell transplantation in patients with an unrelated donor Profylactisch infusie van CD4 positieve donor lymfocyten vroeg na een T-cel gedepleteerde stamceltransplantatie bij patienten met een onverwante donor

Ongoing
2
60
Europe
CD4 positive cells, CD4+ cells, Infusion
Leiden University Medical Center, Leiden University Medical Center
Patients with AML, MDS, ALL, CML in accelerated phase or blastic transformation, CLL, MM or aggressive lymphoma, who underwent a (non) myeloablative allo-SCT with an unrelated donor. Patienten met AML, MDS, ALL, CML in geaccelereerde fase of blastische transformatie, CLL, MM of agressief lymfoom, die een (non) myeloablatieve allo-SCT met een onverwante donor hebben ondergaan., Hematological malignant diseases hematologische kwaadaardige aandoeningen, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2011-005562-38: Safety and Efficacy of peripheral blood stem cell transplantation using specifically purified stem cell preparations derived from patient family members in paediatric and adult patients Sicherheit und Wirksamkeit der Blutstammzelltransplantation mit spezifisch aufgereinigten Stammzellpräparaten von Famililienmitgliedern der Patienten als Spender bei Kindern und Erwachsenen

Ongoing
2
60
Europe
TCRabCD19PBSC, TCRabCD19PBSC_cryo, Suspension for injection
Miltenyi Biotec GmbH, Miltenyi Biotec GmbH
Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor. Hämatologische oder nicht-hämatologische maligne Erkrankungen oder nicht bösartige Erkrankungen, die einer allogenen Blutstammzelltransplantation eines haploidentischen Spenders bedürfen., Severe diseases requiring allogenic blood stem cell transplantation. Schwere Erkrankungen, die einer allogenen Blutstammzelltransplantation bedürfen., Diseases [C] - Cancer [C04]
 
 
NCT01534767: Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Recruiting
2
19
US
sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenstrom Macroglobulinemia
06/13
10/13
NCT01414127: Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT

Active, not recruiting
2
22
US
tacrolimus, FK 506, Prograf, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell
Barbara Ann Karmanos Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
10/13
10/13
AHOD03P1, NCT00107198: Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Active, not recruiting
2
188
Canada, US, RoW
Conventional Surgery, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
10/15
12/30
2006-003243-23: A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma

Ongoing
2
45
Europe
GEMZAR*INFUS 1FL 1G POLV, GEMZAR*1FL 200MG POLV, ELOXATIN*IV 1FL POLV 50MG, MABTHERA*EV 1FL 50ML 500MG, HOLOXAN*IV 1FL 1G+FL 50ML SOLV, MABTHERA*EV 2F 10ML 100MG, ELOXATIN*IV 1FL POLV 100MG, GEMZAR*INFUS 1FL 1G POLV, GEMZAR*1FL 200MG POLV, ELOXATIN*IV 1FL POLV 50MG, MABTHERA*EV 1FL 50ML 500MG, HOLOXAN*IV 1FL 1G+FL 50ML SOLV, MABTHERA*EV 2F 10ML 100MG, ELOXATIN*IV 1FL POLV 100MG
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE \"G. PASCALE\"
Patients with Relapsed and Primary Refractory Lymphoma
 
 
2006-000251-18: Phase II Cardiac Safety trial of liposomal pegillated doxorrubicine in patients with breast cancer with non evidence of disease and previous exposition to Antraciclines.Estudio Fase II de Seguridad Cardiaca de Doxorubicina Liposomal Pegilada (Caelyx R) en pacientes con cáncer de mama en estadios NED (sin Evidencia de Enfermedad) y previamente tratados con Antraciclinas

Ongoing
2
47
Europe
Caelyx®, Caelyx®, Caelyx®
Dr. Llombart Cussac
Non evidence of disease (NED) Breast cancer.
 
 
2006-005004-14: A phase II study about the use of intensified hybrid chemotherapy regimen ChLVVP/ABVVP in advanced Hodgkin lymphoma patients.

Ongoing
2
106
Europe
VELBE EV 1FL 10MG, LEUKERAN 25CPR RIV 2MG, NATULAN 50CPS 50MG, DELTACORTENE FORTE 10CPR 25MG, DOXORUBICINA EBEWE IV 10MG/5ML, VELBE EV 1FL 10MG, LEUKERAN 25CPR RIV 2MG, NATULAN 50CPS 50MG, DELTACORTENE FORTE 10CPR 25MG, DOXORUBICINA EBEWE IV 10MG/5ML
ISTITUTO EUROPEO DI ONCOLOGIA
Hodgkin s disease
 
 
2007-007168-94: PHASE II MULTICENTRE CLINICAL STUDY WITH EARLY TREATMENT INTENSIFICATION IN PTS WITH HIGH-RISK HODGKIN LYMPHOMA, IDENTIFIED AS FDG-PET SCAN POSITIVE AFTER TWO CONVENTIONAL ABVD COURSES

Ongoing
2
450
Europe
Dacarbazine, ADRIBLASTINA, BLEOMICINA CRIN, VINBLASTINA BAX, ADRIBLASTINA, BLEOMICINA CRIN, VINBLASTINA BAX
AZIENDA OSPEDALIERA \"S. CROCE E CARLE\"
HD ADVANCED DISEASE
 
 
2008-004955-31: Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET Positive Hodgkin Lymphoma.Key words: Reduced intensity conditioning, Transplantation, Hodgkin lymphoma

Ongoing
2
49
Europe
Fludarabine, Melphalan, Alemtuzumab,
University College London
Relapsed Hodgkin Lymphoma
 
 
2009-016588-12: ENSAYO FASE II PARA VALORAR LA COMBINACIÓN DE LENALIDOMIDA CON DOSIS METRONÓMICAS DE CICLOFOSFAMIDA EN PACIENTES CON LINFOMA DE HODGKIN CLÁSICO REFRACTARIO O EN RECAÍDA

Ongoing
2
16
Europe
LENALIDOMIDA 20 mg, CICLOFOSFAMIDA, REVLIMID 5 mg cápsulas duras, REVLIMID 10 mg càpsulas duras, REVLIMID 15 mg cápsulas duras, REVLIMID 25 mg cápsulas duras, REVLIMID 5 mg cápsulas duras, REVLIMID 10 mg càpsulas duras, REVLIMID 15 mg cápsulas duras, REVLIMID 25 mg cápsulas duras
Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL)
Linfoma de Hodgkin clásico recidivado o refractario.
 
 
2015-003318-26: Phase II, open-label, not comparative, multicenter study of multiple doses of NEPA (Netupitant+Palonosetron) in preventing chemotherapy induced nausea and vomiting(CINV) in patient with Non Hodgkin’s Lymphomareceiving salvage chemotherapy followed by high dose chemotherapy and autologous hematopoietic stem cells support. Studio di fase II, in aperto, non comparativo, multicentrico, di dosi ripetute di NEPA (netupitant + palonosetron) nella prevenzione della nausea ed il vomito indotti da chemioterapia (CINV) in pazienti con Linfoma Non-Hodgkin trattati con chemioterapia di salvataggio seguita da alte dosi di chemioterapia con supporto di cellule staminali ematopoietiche

Ongoing
2
81
Europe
AKYNZEO, EU/1/15/1001/001, Capsule, hard, AKYNZEO
ASSOCIAZIONE SALENTINA ANGELA SERRA ONLUS, ITALFARMACO S.P.A.
NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, Diseases [C] - Cancer [C04]
 
 
2017-002544-32: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma fit for autologous stem cell transplant who fail to reach complete metabolic remission after first or second line salvage therapy

Not yet recruiting
2
120
Europe
Opdivo, BMS-936558, Concentrate for solution for infusion, Opdivo
University College London, Bristol-Myers Squibb Pharmaceuticals Ltd
Relapsed/refractory Hodgkin lymphoma, Hodgkin lymphoma is a cancer of the lymphatic system due to abnormal lymphocytes. Refractory means not responding to initial treatment. Relapse is where disease returns after initial response., Diseases [C] - Cancer [C04]
 
 
NCT02396134: Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Active, not recruiting
2
61
US
CMVpp65-A*0201 peptide vaccine, Placebo, placebo, Placebo, placebo therapy, PLCB, sham therapy, Laboratory Biomarker Analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
03/18
12/24
NCT02639559: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Completed
2
50
US
BL-8040, Leukapheresis, Hematopoietic cell transplant
Washington University School of Medicine, BioLineRx, Ltd.
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
04/18
04/23
NCT01743131: Abatacept as GVHD Prophylaxis Phase 2

Active, not recruiting
2
186
Canada, US
Abatacept, Orencia, placebo
Boston Children's Hospital, FDA Office of Orphan Products Development
Graft vs Host Disease, Malignancy
06/18
09/23
 

Download Options